efpeglenatide (SAR439977)

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited, Sanofi

Conditions

Type 2 Diabetes Mellitus

Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

CompletedNCT03353350

Hanmi Pharmaceutical Company LimitedType 2 Diabetes Mellitus

Start: 2017-12-05End: 2020-09-07Updated: 2022-01-18

Effect of Efpeglenatide on Cardiovascular Outcomes

TerminatedNCT03496298

SanofiType 2 Diabetes Mellitus

Start: 2018-04-27End: 2020-12-10Updated: 2021-10-15

Related Papers

Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

Circulation2023-02-2022 citations

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Circulation2021-11-14118 citations

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

New England Journal of Medicine2021-06-28714 citations